TY - JOUR
KW - Administration, Inhalation
KW - Adrenal Cortex Hormones
KW - Adrenergic beta-2 Receptor Agonists
KW - Bronchodilator Agents
KW - Chlorobenzenes
KW - Cross-Sectional Studies
KW - Drug Combinations
KW - Humans
KW - Muscarinic Antagonists
KW - Nebulizers and Vaporizers
KW - Primary health care
KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy
KW - Quinuclidines/adverse effects
KW - chronic obstructive pulmonary disease
KW - multiple-inhaler triple therapy
KW - patient characteristics
KW - single-inhaler triple therapy
KW - triple therapy
AU - K. Rothnie
AU - S. Joksaite
AU - L. Sansbury
AU - C. Compton
AU - V. Di Boscio
AU - A. Ismaila
AD - Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK.
Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, Research Triangle Park, NC, USA.
Global Medical Affairs, GlaxoSmithKline, Middlesex, UK.
Global Medical Affairs, GlaxoSmithKline, Ealing, UK.
Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, Collegeville, PA, USA.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
AN - 35769225
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC9234193
DO - 10.2147/copd.s338436
DP - NLM
ET - 2022/07/01
LA - eng
N1 - 1178-2005
Rothnie, Kieran J
Joksaite, Sandra
Sansbury, Leah B
Compton, Chris
Di Boscio, Valentina
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Journal Article
Observational Study
Int J Chron Obstruct Pulmon Dis. 2022 Jun 22;17:1455-1466. doi: 10.2147/COPD.S338436. eCollection 2022.
PY - 2022
SN - 1176-9106 (Print)1176-9106
SP - 1455
EP - 1466
T2 - Int J Chron Obstruct Pulmon Dis
TI - Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
VL - 17
ER -